104775-36-2|Ecabapide|Benzamide, 3-((2-((2-(3,4-dimethoxyphenyl)ethyl)amino)-2-oxoethyl)amino)-N-methyl-|-范德生物科技公司

Ecabapide

NMR下载 COA and HPLC MSDS下载
names：
Benzamide, 3-((2-((2-(3,4-dimethoxyphenyl)ethyl)amino)-2-oxoethyl)amino)-N-methyl-
CAS号：
104775-36-2
MDL Number：
MF(分子式)： C20H25N3O4 MW(分子量)： 371.437
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Ecabapide
英文别名	Ecabapide; DQ-2511; DQ 2511; DQ2511
CAS号	104775-36-2
Inchi	InChI=1S/C20H25N3O4/c1-21-20(25)15-5-4-6-16(12-15)23-13-19(24)22-10-9-14-7-8-17(26-2)18(11-14)27-3/h4-8,11-12,23H,9-10,13H2,1-3H3,(H,21,25)(H,22,24)
InchiKey	JTAGHJPZEDNHHA-UHFFFAOYSA-N
分子式 Formula	C20H25N3O4
分子量 Molecular Weight	371.437
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Ecabapide(CAS:104775-36-2):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Ecabapide is a a novel gastroprokinetic agent found to significantly enhance gastric emptying of SHRSP at 1 mg/kg in single administration, 0.3 and 1 mg/kg in 2-week treatment and 7.7 mg/kg in 4-week (diet) exposure. The effect of ecabapide has been found to be exerted without showing tachyphylaxis.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Fujimaki Y, Hosokami T, Ono K. Identification of urinary metabolites of ecabapide in rat. Xenobiotica. 1995 May;25(5):501-10. PubMed PMID: 7571723.

[2]Yokotani K, Okuma Y, Osumi Y. Alpha-2-adrenoceptor-mediated inhibition of vagally induced gastric acid secretion with the anti-ulcer agent DQ-2511. Jpn J Pharmacol. 1988 Oct;48(2):299-302. PubMed PMID: 2850383.

[3] Hatanaka S, Ryokawa Y, Kawarabayashi K, Furuhama K. DQ-2511, having an antiulcer action, elicits vasodilation through an increase in cyclic GMP contents in rat arteries. Pharmacology. 1995 Sep;51(3):174-9. PubMed PMID: 7501703.

[4] Furuhama K, Wood JD. Pharmacology of the gastric pro-kinetic drug ecabapide (DQ-2511). J Pharm Pharmacol. 1997 Dec;49(12):1168-74. Review. PubMed PMID: 9466337.

[5] Fujimaki Y, Arai N, Inaba T. Identification of cytochromes P450 involved in human liver microsomal metabolism of ecabapide, a prokinetic agent. Xenobiotica. 1999 Dec;29(12):1273-82. PubMed PMID: 10647912.

6: Hatanaka S, Hosokami T, Kawarabayashi K, Iseri M, Tsubokura K, Furuhama K. Pharmacological characteristics of DQ-2511 as a prokinetic agent. Arch Int Pharmacodyn Ther. 1995 Nov-Dec;330(3):332-44. PubMed PMID: 8836452.7: Asano M, Kurebayashi Y, Ryokawa Y, Hashizume T, Akashi A. Antiulcer effects of 3-[[[2-(3,4-dimethoxyphenyl)ethyl] carbamoyl]methyl]-amino-N-methylbenzamide in experimental gastric and duodenal ulcers. Arzneimittelforschung. 1990 Mar;40(3):276-81. PubMed PMID: 2346535.8: Nakaoka M, Tsumura M, Ichikawa E, Suzuki W, Hakusui H, Nakazawa T. Identification of major biliary and urinary metabolites of ecabapide in rats. Xenobiotica. 1996 Sep;26(9):983-94. PubMed PMID: 8893045.9: Sakai H, Ikari A, Kumano E, Takeguchi N. A cyclic GMP-dependent housekeeping Cl- channel in rabbit gastric parietal cells activated by a vasodilator ecabapide. Br J Pharmacol. 1996 Dec;119(8):1591-9. PubMed PMID: 8982506; PubMed Central PMCID: PMC1915798.10: Niijima A, Hatanaka S, Furuhama K. Effects of DQ-2511 on neutral activity in afferent and efferent loops of gastric vago-vagal reflex pathways in the rat. J Auton Pharmacol. 1996 Feb;16(1):49-53. PubMed PMID: 8736431.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开